Clinical Trial Update: Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pemigatinib for metastatic or unresectable colorectal cancer with FGFR alterations; status and results details are not provide…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2 | Status: UNKNOWN | Results posted: 2024-02-21